BioSpace News Archive

4D pharma to Participate in 5 th Microbiome Movement Drug Development Summit Europe

Viz.ai has announced the launch of Viz RECRUIT , cutting edge software that uses artificial intelligence to accelerate clinical studies. Viz RECRUIT uses AI to automatically detect a suspected disease such as a brain hemorrhage, a tumor, or a cardiac structural abnormality, and uses that insight to ensure the right doctor is notified abo

Bristol Myers Squibb (NYSE:BMY) today announced that it has changed the timing of its previously announced earnings conference call. The Company will now host a conference call to discuss results for the fourth quarter of 2020 on Thursday, February 4, 2021 at 10 a.m. ET. During the call, company executives will review financial results and address inquiries from investors and analysts. Investors and the general public ar

The FDA Is In The Process Of Investigation And Conducting Their Due Diligence For Efficacy And Safety

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the publication of results from the CAPLYTA clinical trial (ITI-007-303) in adult patients with schizophrenia.

Protech Home Medical Corp. (the “Company”) (TSXV: PTQ) (OTCQX: PTQQF), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, today announced that it will host its Q4 and Full Year Fiscal 2020 earnings conference call and audio webcast on Friday, January 29, 2021 at 10:00 a.m. (EST).

Aditx Therapeutics, Inc., a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, announced the operational launch of the AditxtScore™ Immune Monitoring Platform as of February 1st, 2021.

Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced

Dermata Therapeutics, LLC, a privately held biotechnology company focused on advanced treatments in medical and aesthetic dermatology, announced today that results from its Phase 2b study of DMT310 for the treatment of moderate to severe acne have been accepted as a poster presentation at the 2021 Maui Derm for Dermatologists Annual Conference,

Proven physician leader to assume a wide range of governance and leadership responsibilities on behalf of 8 Permanente Medical Groups